Do analysts prefer QLGN or BPTSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, QLGN or BPTSY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is QLGN or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Biophytis N/A N/A N/A

Do analysts prefer PRFX or BPTSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, PRFX or BPTSY?

PainReform has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PainReform $20K 80.04 -$5.02M -$736.66 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is PRFX or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Biophytis N/A N/A N/A

Do analysts prefer CANF or BPTSY?

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,316.67%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, CANF or BPTSY?

Can-Fite BioPharma has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Can-Fite BioPharma $405K 4.85 -$7.63M -$35.80 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is CANF or BPTSY more profitable?

Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Biophytis N/A N/A N/A

Which has better earnings & valuation, ORGS or BPTSY?

Biophytis has lower revenue, but higher earnings than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orgenesis $662K 2.68 -$55.36M -$11.51 N/A Biophytis N/A N/A -$18.43M N/A N/A

Is ORGS or BPTSY more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Biophytis N/A N/A N/A

Do analysts recommend BPTSY or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biophytis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, BPTSY or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Biophytis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Universe Pharmaceuticals $17.86M 0.09 -$3.67M N/A N/A

Is BPTSY or UPC more profitable?

Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Universe Pharmaceuticals N/A N/A N/A

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)

As of 06/15/2026

Compare

BPTSY vs. QLGN, PRFX, CANF, ORGS, and UPC

Should you buy Biophytis stock or one of its competitors? MarketBeat compares Biophytis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biophytis include Qualigen Therapeutics (QLGN), PainReform (PRFX), Can-Fite BioPharma (CANF), Orgenesis (ORGS), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical products" industry.

How does Biophytis compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Biophytis	N/A	N/A	N/A

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Biophytis	Neutral

Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Qualigen Therapeutics and Biophytis tied by winning 3 of the 6 factors compared between the two stocks.

How does Biophytis compare to PainReform?

PainReform (NASDAQ:PRFX) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

37.3% of PainReform shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, PainReform had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for PainReform and 0 mentions for Biophytis. PainReform's average media sentiment score of 0.30 beat Biophytis' score of 0.00 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Neutral
Biophytis	Neutral

PainReform has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	80.04	-$5.02M	-$736.66	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

PainReform has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

Summary

PainReform beats Biophytis on 7 of the 8 factors compared between the two stocks.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	4.85	-$7.63M	-$35.80	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Biophytis	N/A	N/A	N/A

Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,316.67%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Biophytis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Biophytis. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Biophytis	Neutral

Summary

Can-Fite BioPharma beats Biophytis on 7 of the 9 factors compared between the two stocks.

How does Biophytis compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Orgenesis has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Biophytis	Neutral

Biophytis has lower revenue, but higher earnings than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	2.68	-$55.36M	-$11.51	N/A
Biophytis	N/A	N/A	-$18.43M	N/A	N/A

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Biophytis	N/A	N/A	N/A

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to Universe Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Universe Pharmaceuticals	N/A	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than Biophytis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Universe Pharmaceuticals	$17.86M	0.09	-$3.67M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biophytis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.1% of Biophytis shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Biophytis. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Biophytis. Universe Pharmaceuticals' average media sentiment score of 1.87 beat Biophytis' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Biophytis	Neutral
Universe Pharmaceuticals	Very Positive

Summary

Universe Pharmaceuticals beats Biophytis on 7 of the 8 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTSY vs. The Competition

Export

Metric	Biophytis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$586K	$763.44M	$6.49B	$12.35B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	N/A	1.43	23.87	24.26
Price / Sales	N/A	127.26	524.24	106.62
Price / Cash	N/A	20.06	44.13	56.68
Price / Book	-0.02	7.92	10.50	6.69
Net Income	-$18.43M	-$4.88M	$3.56B	$337.12M
7 Day Performance	N/A	2.08%	0.88%	2.17%
1 Month Performance	N/A	1.63%	1.53%	3.64%
1 Year Performance	-81.88%	44.88%	26.46%	29.77%

Biophytis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
QLGN Qualigen Therapeutics	N/A	$1.37 -1.4%	N/A	-61.9%	$2.32M	N/A	N/A	50	Gap Up
PRFX PainReform	0.5618 of 5 stars	$1.84 -26.1%	N/A	-79.2%	$2.16M	$20K	N/A	4	Gap Down
CANF Can-Fite BioPharma	1.7903 of 5 stars	$3.00 +0.3%	$42.50 +1,316.7%	-86.8%	$1.97M	$405K	N/A	8	News Coverage
ORGS Orgenesis	N/A	$0.34 -23.6%	N/A	-81.7%	$1.78M	$662K	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 6/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biophytis (BPTSY) Competitors

BPTSY vs. QLGN, PRFX, CANF, ORGS, and UPC

How does Biophytis compare to Qualigen Therapeutics?

Summary

How does Biophytis compare to PainReform?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Summary

How does Biophytis compare to Orgenesis?

Summary

How does Biophytis compare to Universe Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biophytis (BPTSY) Competitors

BPTSY vs. QLGN, PRFX, CANF, ORGS, and UPC

How does Biophytis compare to Qualigen Therapeutics?

Which has better valuation and earnings, QLGN or BPTSY?

Is QLGN or BPTSY more profitable?

Does the media refer more to QLGN or BPTSY?

Which has more risk & volatility, QLGN or BPTSY?

Do analysts prefer QLGN or BPTSY?

Do insiders & institutionals believe in QLGN or BPTSY?

Summary

How does Biophytis compare to PainReform?

Is PRFX or BPTSY more profitable?

Do institutionals and insiders believe in PRFX or BPTSY?

Do analysts prefer PRFX or BPTSY?

Does the media refer more to PRFX or BPTSY?

Which has higher valuation and earnings, PRFX or BPTSY?

Which has more volatility & risk, PRFX or BPTSY?

Summary

How does Biophytis compare to Can-Fite BioPharma?

Which has stronger valuation and earnings, CANF or BPTSY?

Is CANF or BPTSY more profitable?

Which has more volatility and risk, CANF or BPTSY?

Do insiders & institutionals hold more shares of CANF or BPTSY?

Do analysts prefer CANF or BPTSY?

Does the media refer more to CANF or BPTSY?

Summary

How does Biophytis compare to Orgenesis?

Do insiders & institutionals hold more shares of ORGS or BPTSY?

Which has more volatility and risk, ORGS or BPTSY?

Does the media prefer ORGS or BPTSY?

Which has better earnings & valuation, ORGS or BPTSY?

Is ORGS or BPTSY more profitable?

Summary

How does Biophytis compare to Universe Pharmaceuticals?

Which has more risk & volatility, BPTSY or UPC?

Is BPTSY or UPC more profitable?

Which has stronger valuation and earnings, BPTSY or UPC?

Do analysts recommend BPTSY or UPC?

Do institutionals & insiders believe in BPTSY or UPC?

Does the media refer more to BPTSY or UPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTSY vs. The Competition

Biophytis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools